Polyethylene glycol-modified interleukin-2 and thymosin alpha 1 in human immunodeficiency virus type 1 infection.

Ramachandran R, Katzenstein DA, Winters MA, Kundu SK, Merigan TC

The Journal of infectious diseases1 Apr 1996Cited by 9 (Europe PMC)

PMID8603940DOI10.1093/infdis/173.4.1005PepBankPUB-08603940

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

01HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In HIV-infected adults on zidovudine and PEG-IL-2, adding thymosin alpha‑1 produced no additional increase in CD4 cell count.
In plain wordsIn adults with HIV, adding thymosin alpha‑1 to a regimen of PEG-IL-2 and zidovudine did not raise CD4 counts further.
Peptide
Thymosin alpha-1
Outcome
No significant changeCD4 T cell count after adding thymosin alpha 1
Study
n = 12
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
but no additional increase in CD4 cell count was observed with thymosin alpha 1.
2 context sentences(design, population, supporting numbers)
Summary · context
The safety and antiviral effects of polyethylene glycolated interleukin-2 (PEG-IL-2) and thymosin alpha 1 in addition to zidovudine were studied in 12 human immunodeficiency virus (HIV)-infected subjects with 50-250 CD4 T cells/mm3.
Summary · context
Thymosin alpha 1 was administered subcutaneously at 400 microgram/m2 after four doses of PEG-IL-2, escalating to 1600 microgram/m2 weekly for an additional 2 months.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-0860394001
02HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In HIV-infected adults, virologic monitoring showed no evidence of increased HIV activation during PEG-IL-2 or thymosin alpha‑1 therapy.
In plain wordsIn adults with HIV, tests showed no sign that PEG-IL-2 or thymosin alpha‑1 therapy increased HIV activity.
Peptide
Thymosin alpha-1
Outcome
No significant changeHIV activation
Study
n = 12
Outcome group
Antiviral activity · Infection
Source sentences
Summary
Virologic monitoring by polymerase chain reaction quantitation of proviral DNA and plasma RNA and p24 antigen assays showed no evidence of increased HIV activation during PEG-IL-2 or thymosin alpha 1 therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
The safety and antiviral effects of polyethylene glycolated interleukin-2 (PEG-IL-2) and thymosin alpha 1 in addition to zidovudine were studied in 12 human immunodeficiency virus (HIV)-infected subjects with 50-250 CD4 T cells/mm3.
Summary · context
Thymosin alpha 1 was administered subcutaneously at 400 microgram/m2 after four doses of PEG-IL-2, escalating to 1600 microgram/m2 weekly for an additional 2 months.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-0860394002
03HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialSafety outcome
In HIV-infected adults, patients tolerated PEG-IL-2 and thymosin alpha‑1 without significant toxicities.
In plain wordsIn adults with HIV, PEG-IL-2 and thymosin alpha‑1 caused no significant toxicity.
Peptide
Thymosin alpha-1
Outcome
No significant changeToxicity
Study
n = 12
Outcome group
Adverse events · Whole body
Source sentences
Summary
Patients tolerated both PEG-IL-2 and thymosin alpha 1 without significant toxicities.
2 context sentences(design, population, supporting numbers)
Summary · context
The safety and antiviral effects of polyethylene glycolated interleukin-2 (PEG-IL-2) and thymosin alpha 1 in addition to zidovudine were studied in 12 human immunodeficiency virus (HIV)-infected subjects with 50-250 CD4 T cells/mm3.
Summary · context
Thymosin alpha 1 was administered subcutaneously at 400 microgram/m2 after four doses of PEG-IL-2, escalating to 1600 microgram/m2 weekly for an additional 2 months.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-0860394003

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT00001036

The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection

National Institute of Allergy and Infectious Diseases (NIAID)n = 12

HIV Infections

Trial page ClinicalTrials.govUpdated 30 Jul 2008

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
10 Oct 2026, 08:55 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC